Recruiting PHASE1/PHASE2 INTERVENTIONAL 2-arm NCT07109219

Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia (ALLight)

A Modular Phase I/II, Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of AZD4512 Monotherapy or in Combination With Anticancer Agent(s) in Participants With Acute Lymphoblastic Leukemia

Sponsor: AstraZeneca

Conditions B-cell Acute Lymphoblastic Leukemia (B-ALL)

Interventions AZD4512 monotherapy

Updated 5 times since 2025 Last updated: Mar 3, 2026 Started: Nov 12, 2025 Primary completion: Apr 28, 2028 Completion: Jul 3, 2028

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT07109219, this PHASE1/PHASE2 trial focuses on B-cell Acute Lymphoblastic Leukemia (B-ALL) and remains actively recruiting participants. Sponsored by AstraZeneca, it has been updated 5 times since 2025, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

5 versions recorded

Mar 2026 — Present [monthly]

Recruiting PHASE1/PHASE2
Feb 2026 — Mar 2026 [monthly]

Recruiting PHASE1/PHASE2
Jan 2026 — Feb 2026 [monthly]

Recruiting PHASE1/PHASE2

Status: Not Yet Recruiting → Recruiting
Oct 2025 — Jan 2026 [monthly]

Not Yet Recruiting PHASE1/PHASE2
Sep 2025 — Oct 2025 [monthly]

Not Yet Recruiting PHASE1/PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AstraZeneca
Fortrea

Data source: AstraZeneca

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Badalona(Barcelona), Spain , Barcelona, Spain , Bloomsbury, United Kingdom , Bunkyō City, Japan , Chicago, United States , Chūōku, Japan , Duarte, United States , Franklin, United States , Guangzhou, China , Houston, United States and 13 more locations